MGMT and neoplasm: The prognostic value is especially valuable in elderly and/or frail patients, in whom the MGMT promoter methylation status should always be assessed before deciding on therapy, as patients without methylated tumors may benefit to a much smaller extent from tumor-specific treatment and chemotherapy (112).